10-Q has been released so I am sure it will receive scrutiny. Of interest is the capital requirements for the balance of this year:

Capital Requirements

Biocurex anticipates that its capital requirements for the twelve months
ending December 31, 2009 will be as follows:


      Business Development                                    $   200,000
      Research, Development and production - Invitro
       diagnostics (rapid tests, blood tests, histology
       tests, production of ASR's)                                700,000
      Payment of Outstanding Liabilities                           80,000
      General and Administrative Expenses                         450,000
      Marketing and Investor Communications                       600,000
      Payment of Principal on Convertible Notes                 1,200,000
      Payment of Interest on Convertible Notes                    198,660
                                                             ------------
                                                               $3,428,660
                                                             ============